Our analysis of clinicopathological characteristics revealed a significant association between PLCH1 expression and receptor status in breast cancer, with elevated PLCH1 levels observed in HER2-positive, ER-positive, and PR-positive breast cancer patients. Here, PGR is linked to breast carcinoma.